Central Sensitization in Chronic Whiplash Patients
Central Sensitization in Chronic Whiplash Patients: Metabolite Concentrations in the Anterior Cingulate Cortex and Periacueductal Gray Matter
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Persistent chronic pain is a common symptom of whiplash leading to reduced quality of life. Little information is available regarding changes in brain processing areas and change in central sensitization to noxious input during the chronic phase of whiplash. Metabolite concentrations in the anterior cingulate cortex and periaqueductal gray matter may be predictors of neuropathic pain and these changes may explain the development of central sensitization in people with chronic whiplash.
Until now, there is not any study that show this approach.
研究の種類
研究の種類
入学 (予想される)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前：Diego Serrano-Muñoz, MsC
- 電話番号：783 +34 925 24 77 00
- メール：dserranomu@externas.sescam.jccm.es
研究連絡先のバックアップ
- 名前：Julian Taylor-Green, PhD
- 電話番号：109 +34 925 24 77 00
- メール：jscott@sescam.org
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients who have suffered whiplash syndrome. By one hand, patients with chronic pain (minimun 8 weeks) and 2 points or more of pain intensity. By the other hand, patiens without pain (2 points or less of pain intensity).
By last, subjects without whiplash syndrome.
説明
Inclusion Criteria:
- Whiplash syndrome
- Chronic pain
- Age between 18 to 65 years
- 4 months to 2 years after the whiplash syndrome
Exclusion Criteria:
- Neurological disease
- Claustrophobia
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：コホート
- 時間の展望：断面図
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Whiplash-Pain
Subjects with chronic whiplash syndrome and pain.
The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks.
Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale.
The minimum will be 2 points.
Subjects will be recruited between the 4 months until 2 years after the whiplash.
|
Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration. The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.
Questionnaires are important to assess the chronic pain and their impact in the quality of life.
For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale.
Also,we will assess the disability after whiplash using the Neck Disability Index.
Conditioned Pain Modulation over the tenar eminence.
The test will be a heat tonic stimulus which evoke a 3-pain intensity.
The conditioning stimulus will be a cold water immersion (12ºC)
|
|
Whiplash-no Pain
Subjects with chronic whiplash syndrome and pain.
The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks.
Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale.
The maximun will be 2 points.
Subjects will be recruited between the 4 months until 2 years after the whiplash.
|
Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration. The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.
Questionnaires are important to assess the chronic pain and their impact in the quality of life.
For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale.
Also,we will assess the disability after whiplash using the Neck Disability Index.
Conditioned Pain Modulation over the tenar eminence.
The test will be a heat tonic stimulus which evoke a 3-pain intensity.
The conditioning stimulus will be a cold water immersion (12ºC)
|
|
Non-injured
Subjects without whiplash syndrome.
The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
|
Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration. The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.
Questionnaires are important to assess the chronic pain and their impact in the quality of life.
For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale.
Also,we will assess the disability after whiplash using the Neck Disability Index.
Conditioned Pain Modulation over the tenar eminence.
The test will be a heat tonic stimulus which evoke a 3-pain intensity.
The conditioning stimulus will be a cold water immersion (12ºC)
|
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Metabolite concentrations
時間枠：Baseline at 0 min
|
The metabolite concentrations will be measured by magnetic resonance (spectroscopy)
|
Baseline at 0 min
|
|
Conditioned Pain Modulation
時間枠：Baseline at 0 min
|
Conditioned Pain Modulation will be measured by a Pathway system (Medoc Ltd)
|
Baseline at 0 min
|
|
Brief Pain Inventory
時間枠：Baseline at 0 min
|
Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
|
Baseline at 0 min
|
|
Neurophatic Pain Symptoms Inventory
時間枠：Baseline at 0 min
|
Neurophatic Pain Symptoms Inventory (NPSI), it is used to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
|
Baseline at 0 min
|
|
Pain Catastrophizing Helplessness Subscale
時間枠：Baseline at 0 min
|
Pain Catastrophizing Helplessness Subscale it is used to assess the catastrophizing score
|
Baseline at 0 min
|
|
Neck Disability Index
時間枠：Baseline at 0 min
|
Neck Disability Index (NDI), it is used to assess the disability after whiplash syndrome
|
Baseline at 0 min
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者：Diego Serrano-Muñoz, MsC、Hospital Nacional de Parapléjicos, Toledo
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (予想される)
一次修了
研究の完了 (予想される)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (見積もり)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- GFSM-HNP
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。